Recombinant activated factor VII

被引：2

作者：

Chin, Christopher ^{[1
]}

机构：

[1] Evelina Childrens Hosp, Guys & St Thomas NHS Fdn Trust, Dept Anaesthesia, London, England

来源：

PEDIATRIC ANESTHESIA | 2006年 / 16卷 / 09期

关键词：

D O I：

10.1111/j.1460-9592.2006.02034.x

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Recombinant FVIIa is effective in hemophilia patients with inhibitors. Case reports and emerging data from completed or ongoing clinical trials suggest that rFVIIa is also effective in a variety of bleeding conditions in nonhemophilia patients. Recombinant FVIIa has also been shown to be life saving in some patients with life-threatening hemorrhage and its use in such cases seems warranted. However rFVIIa is not always effective in controlling bleeding, whether due to inadequate dosing, simple failure of the agent or to other causes (27-30). Several questions pertaining to the use of rFVIIa still need to be answered including the mechanism of action and laboratory tests for monitoring. Despite the plethora of case reports, the need for RCT in children that address the questions related to definitive indications for rFVIIa, dose and potential side effects remains. © 2006 The Authors.

引用

页码：907 / 909

页数：3

共 31 条

[1] Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors [J].

Abshire, T ;

Kenet, G .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (06) :899-909

[2] The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients [J].

Aldouri, M .

PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2002, 32 :41-46

[3] MATURATION OF THE HEMOSTATIC SYSTEM DURING CHILDHOOD [J].

ANDREW, M ;

VEGH, P ;

JOHNSTON, M ;

BOWKER, J ;

OFOSU, F ;

MITCHELL, L .

BLOOD, 1992, 80 (08) :1998-2005

[4] Recombinant Factor VIIa improves coagulopathy caused by liver failure [J].

Brown, JB ;

Emerick, KM ;

Brown, DL ;

Whitington, PF ;

Alonso, EM .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2003, 37 (03) :268-272

[5] Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study [J].

Chuansumrit, A ;

Wangruangsatid, S ;

Lektrakul, Y ;

Chua, MN ;

Capeding, MRZ ;

Bech, OM .

BLOOD COAGULATION & FIBRINOLYSIS, 2005, 16 (08) :549-555

[6] Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures [J].

Cooper, HA ;

Jones, CP ;

Campion, E ;

Roberts, HR ;

Hedner, U .

HAEMOPHILIA, 2001, 7 (05) :517-522

[7] Prophylactic recombinant factor VIIa administration to an infant with congenital systemic juvenile xanthogranuloma [J].

De Santiago, Jesus ;

Martinez-Garcia, Ernesto ;

Giron, Jorge ;

Salcedo, Concepcion ;

Perez-Gallardo, Antonio .

PEDIATRIC ANESTHESIA, 2006, 16 (09) :974-976

[8] Recombinant factor VIIa for control of hemorrhage: Early experience in critically ill trauma patients [J].

Dutton, RP ;

Hess, JR ;

Scalea, TM .

JOURNAL OF CLINICAL ANESTHESIA, 2003, 15 (03) :184-188

[9] Pharmacokinetics of recombinant activated factor VII (rFVIIa) [J].

Erhardtsen, E .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (04) :385-391

[10] Monitoring coagulation and the clinical effects of recombinant factor VIIa [J].

Gabriel, DA ;

Carr, M ;

Roberts, HR .

SEMINARS IN HEMATOLOGY, 2004, 41 (01) :20-24

← 1 2 3 4 →